Collegium Pharmaceutical Ownership
| COLL Stock | USD 30.50 0.21 0.68% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 40.4 M | Current Value 40.2 M | Avarage Shares Outstanding 30.2 M | Quarterly Volatility 10 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Collegium |
Collegium Stock Ownership Analysis
About 98.0% of the company shares are held by institutions such as insurance companies. The book value of Collegium Pharmaceutical was currently reported as 7.27. The company had not issued any dividends in recent years. Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Collegium Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 152 people. For more info on Collegium Pharmaceutical please contact Vikram Karnani at 781 713 3699 or go to https://www.collegiumpharma.com.Besides selling stocks to institutional investors, Collegium Pharmaceutical also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Collegium Pharmaceutical's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Collegium Pharmaceutical's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Collegium Pharmaceutical Quarterly Liabilities And Stockholders Equity |
|
Collegium Pharmaceutical Insider Trades History
Only 1.64% of Collegium Pharmaceutical are currently held by insiders. Unlike Collegium Pharmaceutical's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Collegium Pharmaceutical's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Collegium Pharmaceutical's insider trades
Collegium Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Collegium Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Collegium Pharmaceutical backward and forwards among themselves. Collegium Pharmaceutical's institutional investor refers to the entity that pools money to purchase Collegium Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1 M | Emerald Advisers, Llc | 2024-09-30 | 827.3 K | Geode Capital Management, Llc | 2024-09-30 | 775.6 K | Massachusetts Financial Services Company | 2024-09-30 | 765.7 K | Victory Capital Management Inc. | 2024-09-30 | 710.7 K | Emerald Mutual Fund Advisers Trust | 2024-09-30 | 662.3 K | Lsv Asset Management | 2024-09-30 | 451.3 K | Charles Schwab Investment Management Inc | 2024-09-30 | 381.5 K | Northern Trust Corp | 2024-09-30 | 364.7 K | Blackrock Inc | 2024-06-30 | 5.8 M | Pacer Advisors, Inc. | 2024-06-30 | 3.4 M |
Collegium Pharmaceutical Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Collegium Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Collegium Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Collegium Pharmaceutical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Collegium Pharmaceutical Outstanding Bonds
Collegium Pharmaceutical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Collegium Pharmaceutical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Collegium bonds can be classified according to their maturity, which is the date when Collegium Pharmaceutical has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Collegium Pharmaceutical Corporate Filings
8K | 14th of November 2024 An amendment to a previously filed Form 8-K | ViewVerify |
| 13th of November 2024 Other Reports | ViewVerify | |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.49) | Earnings Share 2.34 | Revenue Per Share 18.538 | Quarterly Revenue Growth 0.165 | Return On Assets 0.0968 |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.